Centogene NV
NASDAQ:CNTG
Centogene NV
Revenue
Centogene NV
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Centogene NV
NASDAQ:CNTG
|
Revenue
€47.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
BioNTech SE
NASDAQ:BNTX
|
Revenue
€3.8B
|
CAGR 3-Years
99%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
MorphoSys AG
XETRA:MOR
|
Revenue
€238.3m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
Immatics NV
NASDAQ:IMTX
|
Revenue
€54m
|
CAGR 3-Years
20%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Revenue
€684.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
3%
|
|
Formycon AG
XETRA:FYB
|
Revenue
€42.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
See Also
What is Centogene NV's Revenue?
Revenue
47.5m
EUR
Based on the financial report for Dec 31, 2022, Centogene NV's Revenue amounts to 47.5m EUR.
What is Centogene NV's Revenue growth rate?
Revenue CAGR 5Y
8%
Over the last year, the Revenue growth was 12%. The average annual Revenue growth rates for Centogene NV have been -1% over the past three years , 8% over the past five years .